Ken Griffin Cerus Corp Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$1.7 - $2.39 $15,980 - $22,466	9,400 Added 66.2%	23,600 $41,000
Q2 2024 Aug 14, 2024	SELL	$1.62 - $2.04 $28,998 - $36,516	-17,900 Reduced 55.76%	14,200 $24,000
Q1 2024 May 15, 2024	BUY	$1.66 - $2.42 $1,826 - $2,662	1,100 Added 3.55%	32,100 $60,000
Q4 2023 Feb 14, 2024	BUY	$1.25 - $2.35 $7,750 - $14,570	6,200 Added 25.0%	31,000 $66,000
Q3 2023 Nov 14, 2023	BUY	$1.5 - $3.07 $5,850 - $11,973	3,900 Added 18.66%	24,800 $40,000
Q2 2023 Aug 14, 2023	SELL	$1.79 - $2.9 $11,814 - $19,140	-6,600 Reduced 24.0%	20,900 $51,000
Q1 2023 May 15, 2023	SELL	$2.65 - $3.81 $45,580 - $65,532	-17,200 Reduced 38.48%	27,500 $81,000
Q4 2022 Feb 14, 2023	SELL	$3.38 - $4.22 $288,314 - $359,966	-85,300 Reduced 65.62%	44,700 $163,000
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.83 $18,865 - $32,065	5,500 Added 4.42%	130,000 $468,000

156

147M

84.2K

55.5K

Ticker CERS
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 177,090,000
Market Cap $296M
Description
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.